AIDX · 20/20 Biolabs, Inc.
$0.49
-0.02 (-4.10%)
At close · Jul 24
Market Cap
$5.21M
Shares
10.61M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.49
Open$0.51
Day$0.49–0.51
52W$0.49–50.00
Avg vol 30d1.2M
Short int249K · 2.3% float · 1.0d
Short vol16%
DataFeb 2026–Jul 2026
Filing10-Q · May 20
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 20, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Limited
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−37%
below
RSI (14)
31
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
2 of 7 funds reported for Jun 30 · net +710 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.34% of float · ▲ +33.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
7 holders — 13F breadth
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
+17%
Y/Y
Gross margin
30%
expanding
EPS growth
+34%
Y/Y
Balance sheet
$1.0M
net cash
Quant / Vol
risk profile
Volatility
149%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
14.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−37%
Bearish
RSI (14)
31
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
2 of 7 funds reported for Jun 30 · net +710 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.34% of float · ▲ +33.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
7 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $0
Now $0 · 0%
52-wk high $50
vs 50-day avg -37%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Deferred revenue | $0.4M | FY 2025 | — |
| Increase in OneTest MCEDs funded through Maryland program | 225% | FY 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AIDX
this stock
20/20 Biolabs, Inc.
|
$5.21M | — | +16.7% | — | 2.3% |
|
ABT
Abbott Laboratories
|
$179.51B | -19.2% | +5.7% | 28.9 | 1.4% |
|
SYK
Stryker Corp
|
$126.60B | -9.0% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$106.51B | -13.9% | +8.4% | 22.3 | 1.5% |
|
BSX
Boston Scientific Corp
|
$65.77B | -54.3% | +5.5% | 18.5 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AIDX | -5.1% | -16.8% | — | -10.7% | — |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -3.5% | -17.5% | — | -9.6% | — |